Lead is a naturally occurring toxic metal found in the Earth’s crust. Its widespread use has resulted in extensive environmental contamination, human exposure and significant public health problems in many parts of the world.
Important sources of environmental contamination include mining, smelting, manufacturing and recycling activities, and, in some countries, the continued use of leaded paint and leaded aviation fuel. More than three quarters of global lead consumption is for the manufacture of lead-acid batteries for motor vehicles. Lead is, however, also used in many other products, for example pigments, paints, solder, stained glass, lead crystal glassware, ammunition, ceramic glazes, jewellery, toys and some cosmetics and traditional medicines. Drinking water delivered through lead pipes or pipes joined with lead solder may contain lead. Much of the lead in global commerce is now obtained from recycling.
Young children are particularly vulnerable to the toxic effects of lead and can suffer profound and permanent adverse health impacts, particularly on the development of the brain and nervous system. Lead also causes long-term harm in adults, including increased risk of high blood pressure and kidney damage. Exposure of pregnant women to high levels of lead can cause miscarriage, stillbirth, premature birth and low birth weight.
Sources and routes of exposure
People can become exposed to lead through occupational and environmental sources. This mainly results from:
inhalation of lead particles generated by burning materials containing lead, for example during smelting, recycling, stripping leaded paint and using leaded aviation fuel; and
ingestion of lead-contaminated dust, water (from leaded pipes) and food (from lead-glazed or lead-soldered containers).
An additional source of exposure is the use of certain types of traditional medicines and cosmetics. High levels of lead have, for example, been reported in certain types of kohl, as well as in some traditional medicines used in countries such as India, Mexico and Viet Nam. Consumers should therefore take care only to buy and use regulated products.
Young children are particularly vulnerable to lead poisoning because they absorb 4–5 times as much ingested lead as adults from a given source. Moreover, children’s innate curiosity and their age-appropriate hand-to-mouth behaviour result in their mouthing and swallowing lead-containing or lead-coated objects, such as contaminated soil or dust and flakes from decaying lead-containing paint. This route of exposure is magnified in children with a psychological disorder called pica (persistent and compulsive cravings to eat non-food items), who may pick away at and eat leaded paint from walls, door frames and furniture. Exposure to lead-contaminated soil and dust resulting from battery recycling and mining has caused mass lead poisoning and multiple deaths in young children in Nigeria, Senegal and other countries.
Once lead enters the body, it is distributed to organs such as the brain, kidneys, liver and bones. The body stores lead in the teeth and bones, where it accumulates over time. Lead stored in bone may be released into the blood during pregnancy, thus exposing the fetus. Undernourished children are more susceptible to lead because their bodies absorb more lead if other nutrients, such as calcium or iron, are lacking. Children at highest risk are the very young (including the developing fetus) and the economically disadvantaged.
Health effects in children
Lead exposure can have serious consequences for the health of children. At high levels of exposure lead attacks the brain and central nervous system, causing coma, convulsions and even death. Children who survive severe lead poisoning may be left with intellectual disability and behavioural disorders. At lower levels of exposure that cause no obvious symptoms, lead is now known to produce a spectrum of injury across multiple body systems. In particular, lead can affect children’s brain development, resulting in reduced intelligence quotient (IQ), behavioural changes such as reduced attention span and increased antisocial behaviour, and reduced educational attainment. Lead exposure also causes anaemia, hypertension, renal impairment, immunotoxicity and toxicity to the reproductive organs. The neurological and behavioural effects of lead are believed to be irreversible.
There is no known safe blood lead concentration; even blood lead concentrations as low as 5 µg/dL may be associated with decreased intelligence in children, behavioural difficulties and learning problems. As lead exposure increases, the range and severity of symptoms and effects also increase.
Encouragingly, the successful phasing out of leaded gasoline in most countries, together with other lead control measures, has resulted in a significant decline in population-level blood lead concentrations. As of July 2021, leaded fuel for cars and lorries is no longer sold anywhere in the world (1). However, more needs to be done to phase out of lead paint: so far, only 41% of countries have introduced legally binding controls on lead paint (2).
Burden of disease
The Institute for Health Metrics and Evaluation (IHME) estimated that in 2019, lead exposure accounted for 900 000 deaths and 21.7 million years of healthy life lost (disability-adjusted life years, or DALYs) worldwide due to long-term effects on health. The highest burden was in low- and middle-income countries. IHME also estimated that in 2019, lead exposure accounted for 62.5% of the global burden of developmental intellectual disability whose cause is not obvious, 8.2% of the global burden of hypertensive heart disease, 7.2% of the global burden of the ischaemic heart disease and 5.65% of the global burden of stroke (3).
WHO response
WHO has identified lead as one of 10 chemicals of major public health concern needing action by Member States to protect the health of workers, children and women of reproductive age. WHO has made available through its website a range of information on lead, including information for policy-makers, technical guidance and advocacy materials.
WHO has also developed guidelines on clinical management of lead exposure and is preparing guidelines on prevention of lead exposure, which will provide policy-makers, public health authorities and health professionals with evidence-based guidance on the measures that they can take to protect the health of children and adults from lead exposure.
Since leaded paint is a continuing source of exposure in many countries, WHO has joined with the United Nations Environment Programme to form the Global Alliance to Eliminate Lead Paint. WHO is also a partner in a project funded by the Global Environment Facility that aims to support at least 40 countries in enacting legally binding controls on lead paint (4). The phasing out of lead paint by 2020 is one of the priority actions for governments included in the WHO Road map to enhance health sector engagement in the Strategic Approach to International Chemicals Management towards the 2020 goal and beyond.
(1) End of leaded fuel use a “milestone for multilateralism” press release End of leaded fuel use a “milestone for multilateralism” press release; 2021
(2) Global Health Observatory: Regulations and controls on lead paint.
Geneva: World Health Organization; 2021(3) Institute for Health Metrics and Evaluation (IHME). GBD Compare.
Seattle, WA: IHME, University of Washington; 2019.(4) SAICM GEF Project - Lead in Paint Component
Cereghino JJ, Brock J, Meter JCV, Pentry JK, Smith LD, White BG. Carbamazepine for epilepsy. Neurology. 1974;24(5):401.
CAS Article PubMed Google Scholar
Smith TW, Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest. 1970, Dec;49(12):2377–86.
CAS Article PubMed PubMed Central Google Scholar
Buchthal F, Svensmark OLE, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. A.M.a. Arch Neurol. 1960;2(6):624–30.
CAS Article PubMed Google Scholar
Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit. 1998, Feb;20(1):56–9.
CAS Article PubMed Google Scholar
Centre For Reviews and Dissemination. Systematic reviews : CRD's guidance for undertaking reviews in health care. York: University of York; 2009.
Google Scholar
Higgins JPT, Green S, Collaboration C. Cochrane handbook for systematic reviews of interventions. Chichester, England. Hoboken: Wiley; 2008.
Book Google Scholar
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC med res Methodol. 2007, Feb;7(1):10.
Article PubMed PubMed Central Google Scholar
Cooney L, Hawcutt D, Sinha I. The evidence for intravenous theophylline levels between 10-20mg/L in children suffering an acute exacerbation of asthma: a systematic review. PLoS One. 2016;11(4):e0153877.
Article PubMed PubMed Central Google Scholar
Konidari A, Anagnostopoulos A, Bonnett LJ, Pirmohamed M, El-Matary W. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol. 2014;78(3):467–76.
CAS Article PubMed PubMed Central Google Scholar
Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand. 2009;120(6):416–28.
CAS Article PubMed Google Scholar
Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85(12):1675–85.
CAS Article PubMed Google Scholar
Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006, Apr;130(4):1047–53.
CAS Article PubMed Google Scholar
Prybylski JP. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies. Pharmacotherapy. 2015;35(10):889–98.
CAS Article PubMed Google Scholar
Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole—dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71(11):1447–56.
CAS Article PubMed Google Scholar
Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review. Transplant rev. 2009;23:171–7.
Article Google Scholar
Bishara D, Olofinjana O, Sparshatt A, Kapur S, Taylor D, Patel M. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol. 2013;33:329–35.
CAS Article PubMed Google Scholar
Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Boukhadra N, Genin C, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis. 2014, Mar;20(3):464–71.
Article PubMed Google Scholar
Cucherat M. Méta-analyse des essais thérapeutiques. France: Masson; 1997.
Google Scholar
Kullar R, Leonard SN, Davis SL, Delgado G, Pogue JM, Wahby KA, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31(5):441–8.
CAS Article PubMed Google Scholar
Rylance GW, Moreland TA. Drug level monitoring in paediatric practice. Arch Dis Child. 1980;55(2):89–98.
CAS Article PubMed PubMed Central Google Scholar
Turner-Warwick M. Study of theophylline plasma levels after oral administration of new theophylline compounds. Br med J. 1957, Jul 13;2(5036):67–9.
CAS Article PubMed PubMed Central Google Scholar
Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13(1):132.
Article PubMed PubMed Central Google Scholar
Core outcome measures in effectiveness trials (COMET) initiative; Available from: //www.comet-initiative.org. Accessed 7 January 2017.
Boers M, Idzerda L, Kirwan JR, Beaton D, Escorpizo R, Boonen A, et al. Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. J Rheumatol. 2014;41(5):978–85.
Article PubMed Google Scholar
Sinha IP, Gallagher R, Williamson PR, Smyth RL. Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. Trials. 2012;13(1):103.
Article PubMed PubMed Central Google Scholar
Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC med res Methodol. 2007, Jul;7(1):1.
Article Google Scholar
Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115(3):655–61.
Article PubMed Google Scholar
Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107(2):217–21.
CAS Article PubMed Google Scholar
Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83(3):F177–81.
CAS Article PubMed PubMed Central Google Scholar
Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Dolores Pilloni M, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–90.
CAS Article PubMed Google Scholar
Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J med. 1989;321(22):1489–93.
CAS Article PubMed Google Scholar
Greeff O, Van Tonder J, Cromarty D, Lowman W, Becker P, Nell M. A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation. South Afr J Infect Dis. 2015;30(3):89–94.
Google Scholar
Katrak P, Bialocerkowski AE, Massy-Westropp N, Kumar S, Grimmer KA. A systematic review of the content of critical appraisal tools. BMC med res Methodol. 2004;4:22.
Article PubMed PubMed Central Google Scholar
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.
Article PubMed PubMed Central Google Scholar
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ: British Medical Journal. 2011, Oct;343:d5928.
Article PubMed PubMed Central Google Scholar
Critical appraisal skills programme. 12 questions to help you make sense of cohort study; Available from: //media.wix.com/ugd/dded87_e37a4ab637fe46a0869f9f977dacf134.pdf. Accessed 11 January 2017.
National institute of clinical excellence defined criteria for quality assessment of case series; Available from: //www.nice.org.uk/guidance/cg3/resources/appendix-4-quality-of-case-series-form2. Accessed 11 January 2017.
Page 2
Cooney 2016 [8] | Aminophylline | Asthma | No | 12 | Yes | No restrictions | No | Medine, CINAHL, Cochrane Central, and Web of Science | Cochrane tool for assessment of risk of bias [35], CASP tool [36] | No |
Sparshatt 2009 [10] | Amisulpride | Schizophrenia/schizoaffective disorder | No | 10 | Yes | No restrictions | No | Embase, Medline and PubMed | None | No |
Sparshatt 2010 [14] | Aripirazole | No specific diagnosis | No | 8 | No | No restrictions | Yes | Embase, Medline, and PubMed | None | No |
Knight 2008 [11] | Mycophenolate Mofetil | Transplant patients | No | 12 | Yes | RCTs, Observational studies | No | Medline, Embase, Cochrane Central, Transplant Library, Clinical trial registries | None | No |
Zuk 2009 [15] | Mycophenolate Mofetil | Heart transplant | No | 7 | No | No restrictions | Yes | Medline Embase | None | No |
Bishara 2013 [16] | Olanzapine | Schizophrenia/schizoaffective disorder/bipolar disorder | No | 30 | Yes | No restrictions | Yes | PubMed, Medline, Embase | None | Yes |
Konidari 2014 [9] | Thiopurine | IBD | No | 15 | Yes | RCTs, Observational studies | Yes | PubMed, Medline, UK national health system database | NICE defined criteria for quality assessment of case series [37] | No |
Moreau 2014 [17] | Thiopurine | IBD | Yes | 17 | No | No restrictions | Yes | Medline, Cochrane Library, DirectScience, and Google Scholar | Nonea | Yes |
Osterman 2006 [12] | Thiopurine | IBD | No | 12 | No | No restrictions | No | Medline, PubMed Plus | None | Yes |
Prybylski 2015 [13] | Vancomycin | S. aureus bacteraemia | No | 14 | No | Observational studies | No | PubMed | None | Yes |
- RoB Risk Of bias, IBD Inflammatory Bowel Disease, RCT Randomised controlled trial, CENTRAL Central Register of Controlled Trials
- aMoreau et al. used the MOOSE consensus statement to assess reporting quality, but do not report the results of their assessment